tbuckley/cabot-search huggingface dataset:
TV: Fighting Fat, Fighting Fit
Authors: P. Hammond
Journal: BMJ (1999)

Weight of the Nation , BBC1, 5January; Fat Free , BBC1, a 6part documentary series, from 7January; Fat Files , BBC2, a 3part Horizon documentary, from 7January

This is the big one for obesity—the BBC's largest ever health campaign, with 30dedicated programmes in seven weeks, plugs everywhere on local and national radio and TV, and a registration scheme aimed not just at providing information but at “motivating behavioural change.” The BBC has even informed every health authority in the hope of getting health professionals across Britain “on message.” Throw away the scales. Never say diet. It's the small but permanent changes to eating and activity that are the key to getting fit and feeling great.

The BBC has been down this way before. Terry Wogan launched a Fight the Flab radio campaign in the 1970s and admitted to miming pull ups over the microphone. In 1993Wogan fronted The Health Show , a live, celebrity led extravaganza on BBC1 with Dr Hilary Jones. The cornerstone programme of this …
TCT-36 Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial
Authors: Philip Green, Mark Russo, Suzanne Arnold, Darshan Doshi, Augusto Pichard, Wilson Szeto, Raj Makkar, Vasilis Babaliaros, William Fearon, Lars Svensson, John Webb, Tamim Nazif, Alan Zajarias, Nishath Quader, Rupa Parvataneni, Ajay Kirtane, David Cohen, Michael Mack, Martin Leon
Journal: Journal of the American College of Cardiology (2016)
Foot orthoses research: identifying limitations to improve translation to clinical knowledge and practice
Authors: Ian B Griffiths, Simon K Spooner
Journal: British Journal of Sports Medicine (2016)

Foot orthoses are employed to treat musculoskeletal injury. Research in this field has increased greatly in the past two decades, with researchers publishing ‘placebo’ and ‘sham’-controlled trials within the foot orthoses literature1 ,2 which appears encouraging. However, there are insufficient predictive models for the myriad of musculoskeletal injuries that are being attempted to be treated, let alone a firm understanding of how the design variables of the foot orthoses employed within such studies are influencing the biomechanics of the injured tissues.

Foot orthoses can only exert their therapeutic effects either psychologically (via a placebo effect) and/or by directly modifying reaction forces at the foot–orthosis interface in terms of their magnitudes, location and timing.3 Traditionally, foot orthoses were assumed to exert their primary effects via kinematic change and realigning the skeleton, but this seems unlikely.4 Musculoskeletal injury relates to tissue loading, and clearly, foot orthoses may induce a change in tissue loading without a significant change in foot kinematics.5 Thus, foot …
TCT-450 Bare Metal Stent, Durable Polymer Drug Eluting Stent, or Biodegradable Polymer Drug Eluting Stent in Patients with Diabetes Mellitus - A Mixed Treatment Comparison Analysis of 63,940 Patient-Years of Follow-up from Randomized Trials
Authors: Bora Toklu, Sripal Bangalore, Upendra Kaul, Michael Attubato, Frederick Feit, Deepak Bhatt
Journal: Journal of the American College of Cardiology (2016)
TCT-394 Impact of inadequate angiographic results after pre-dilatation on clinical outcomes following drug-coated balloon treatment for in-stent restenosis
Authors: Akihito Tanaka, Azeem Latib, Richard Jabbour, Hiroyoshi Kawamoto, Marco Ancona, Damiano Regazzoli, antonio Mangieri, francesco giannini, Lorenzo Azzalini, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Antonio Colombo
Journal: Journal of the American College of Cardiology (2016)
Understanding the choice of participating in clinical trials
Authors: C. Catania, T. M. De Pas, A. Goldhirsch, D. Radice, L. Adamoli, M. Medici, E. Verri, C. Marenghi, F. de Braud, F. Nolè
Journal: Journal of Clinical Oncology (2007)

9091 Background: The choice of whether to participate in a clinical trial by patients (pts) with cancer can be influenced, beyond trial information, by patient's own emotional and cultural properties, including past history as well as prejudices. Our hypothesis was that a better knowledge of these cultural and emotional features might be useful to improve patients-doctor dialogue, leading patients to a more conscious motivation to make the choice. Methods: We developed a 17-items, multiple-choice and open-answer questionnaire, to capture motivations for participating, or declining to take part, in clinical trials. Further information included family relationships, schooling and clinical symptoms. Patients were required to have advanced lung or breast cancer and to have never discussed participation in a clinical trial. Results: The questionnaire was answered by all the 42 pts who received it. Eighty-three percent of pts were positive about their participation. Trust in the investigator (43%) or in the Institute (21%) and hope to receive a new chance for cure (71%), both for themselves and for others, were a major motivation for a positive answer. Forty-eight percent thought participation in a clinical trial as a sign that no other “standard” treatments are available; 19% were worried of unknown side effects and 76% considered detailed information on expected toxicity to be helpful in making the decision. Sixty percent of patients were afraid of losing “precious time” by participating in a trial; 9% felt exploited as “guinea pigs” and 31% had a some degree of fear that a clinical trial is primarily motivated by economical interests. The most important reasons for accepting an oral experimental drug were its easy use (46%) and having more freedom (36%) Conclusions: Italian patients with advanced breast or lung cancer positively viewed participation in a clinical trial. Several hopes, prejudices and fears have been captured by the questionnaire, which might lead to improve the informed consent documentation and the consciousness of patients in taking their choice. Validation of the findings in a larger cohort of patients will lead to a study on the effect of a specific intervention on informing patients about clinical research. No significant financial relationships to disclose.
TCT-643 Percutaneous Mitral Valve Repair for Acute Mitral Regurgitation Following an Acute Myocardial Infarction
Authors: Rodrigo Estevez, Tomas Benito-González, Javier Gualis-Cardona, Laura Romero-Roche, Carlota Hernandez, Mario Castaño, Carlos Cuellas-Ramon, David Alonso, Carmen Garrote, Armando Perez de Prado, Maria Lopez, Norberto Alonso-Orcajo, Abel Garcia del Ejido, Felipe Fernandez-Vazquez
Journal: Journal of the American College of Cardiology (2016)
Combination of Sorafenib, Idarubicin, and Cytarabine Has a High Response Rate in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Younger Than 65 Years
Authors: Farhad Ravandi, Jorge Cortes, Stefan Faderl, Guillermo Garcia-Manero, Susan O’Brien, Gautam Borthakur, Sherry Pierce, Mark Brandt, Marites Lang, Weiguo Zhang, Rajyalakshmi Luthra, Dan Jones, Mark J. Levis, Marina Konopleva, Michael Andreeff, Hagop M Kantarjian
Journal: Blood (2008)
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC
Authors: George Blumenschein, Jason Chandler, Edward B. Garon, David Waterhouse, Jonathan W. Goldman, Vijay K. Gunuganti, Ralph Boccia, David Spigel, John Glaspy, Donald A. Berry, Beata Korytowsky, Jin Zhu, Wen Hong Lin, Kelly Bennett, Craig Reynolds
Journal: Journal of Thoracic Oncology (2016)
Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis
Authors: Yaxiong Zhang, Yunpeng Yang, Zhonghan Zhang, Wenfeng Fang, Shiyang Kang, Youli Luo, Jin Sheng, Jianhua Zhan, Shaodong Hong, Yan Huang, Ningning Zhou, Hongyun Zhao, Li Zhang
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Neurokinin-1 receptor antagonists (NK-1RAs) are widely used for chemotherapy-induced nausea and vomiting (CINV) control in patients with highly emetogenic chemotherapy (HEC) and/or moderately emetogenic chemotherapy (MEC). Whether the efficacy and toxicity of antiemesis are different among various NK-1RA-based triple regimens is unknown. Methods: Data of complete responses (CRs) in the acute, delayed, and overall phases and treatment-related adverse events (TRAEs) were extracted from electronic databases. Efficacy and toxicity were integrated by pairwise and network meta-analyses. Results: Thirty-six trials involving 18 889 patients using triple regimens (NK-1RA+serotonin receptor antagonists [5HT3RA] + dexamethasone) or duplex regimen (5HT3RA+dexamethasone) to control CINV were included in the analysis. Different NK-1RA-based triple regimens shared equivalent effect on CRs. In patients with HEC, almost all triple regimens showed statistically significantly higher CRs than duplex regimen (odds ratio [OR]duplex/triple = 0.47–0.66). However, in patients with MEC, only aprepitant-based triple regimen showed better effect than duplex regimen statistically significantly in CRs (ORduplex/triple = 0.52, 95% confidence interval [CI] = 0.34 to 0.68). No statistically significant difference of TRAEs was found among different triple regimens. Palonosetron-based triple regimens were equivalent to first-generation 5HT3RAs-based triple regimens for CRs. Moreover, different doses of dexamethasone plus NK-1RA and 5HT3RA showed no statistically significant difference in CRs. Conclusions: Different NK-1RAs-based triple regimens shared equivalent effect on CINV control. Various triple regimens had superior antiemetic effect than duplex regimen in patients with HEC. Only aprepitant-based triple regimen showed better CINV control compared with duplex regimen in patients receiving MEC. Palonosetron and first-generation 5HT3RAs might share equivalent CINV control in the combination of NK-1RAs and dexamethasone. Lower doses of dexamethasone might be applied when used with NK-1RAs and 5HT3RAs.
Specific delivery of antiproliferative drugs to the hepatic stellate cell; Effects of targeted doxorubicin in bile duct ligated rats.
Authors: R Greupink, H Bakker, M de Ruijter, AM van Loenen-Weemaes, Catharina Reker-Smit, DK Meijer, Leonie Beljaars, Klaas Poelstra
Journal: Hepatology (2004)
Racial differences in perceived risk in participants enrolled in the American College of Radiology (ACRIN-6654) arm of the National Lung Screening Trial (NLST).
Authors: Christopher Lathan, Pallavi Kumar, Ilana F Gareen, Jeremy Gorelick, JoRean Sicks, Kelly Hyland, Elyse R. Park
Journal: Journal of Clinical Oncology (2013)

1563 Background: Blacks in the U.S. have higher incidence and mortality rates of lung cancer (LC) compared to whites. Previous work in small studies suggests that blacks have lower perceived risk of LC which may influence smoking cessation behavior. However, racial disparities in risk perceptions (RP) of LC and smoking related diseases (SRD) in heavy smokers have not been studied. We examined LC and SRD risk perceptions among black and white ACRIN NLST participants. Methods: The 10-item Smoking Risk Perceptions Scale (SRPS) for LC and SRD was administered to NLST participants, from 4 ACRIN sites, with a minimum 30 pack-year smoking history at 1 year following baseline screening chest x-ray or low dose computerized tomography (LDCT). We 1) validated the SRPS in black and white participants separately using exploratory and confirmatory factor analyses, 2) used 2-way ANOVAs to compare RP of black and white participants and 3) used multivariable linear regression models to identify factors associated with RP. Results: Among 1742 white and 194 black participants, the 10 SRPS items loaded onto two factors (absolute and relative risk; Cronbach’s alpha=0.92 and 0.95 for white and black participants, respectively). Black participants had significantly lower RP compared to white participants (SRPS range= 10-50, mean diff. 3.48, 95% CI 2.29-4.68, p&lt;0.01). Factors significantly associated with lower RP in a multivariate linear regression were black race (β=4.59, p &lt; 0.001), former smoking status (β=3.82, p&lt;0.001), male gender (β=1.35, p&lt;0.001), lower education (β=1.16, p =0.010), and older age (years, β = 0.15, p&lt;0.001). Conclusions: We validated the SRPS in black and white ACRIN-6654/NLST participants. Blacks had significantly lower perceptions of LC and SRD risk compared to whites, even after adjusting for study arm, sociodemographics, and smoking status. Sociodemographic factors and smoking status were independently associated with lower RP. These findings confirm that black current and former smokers are at risk of underestimating their smoking-related risk, which may contribute to lower rates of adherence to screening and smoking cessation recommendations.
TCT-224 Real world use of antithrombotic regimens after percutaneous coronary intervention in patients with atrial fibrillation
Authors: Michela Faggioni, Jaya Chandrasekhar, Melissa Aquino, Birgit Vogel, Usman Baber, Samin Sharma, Annapoorna Kini, Serdar Farhan, Jason Kovacic, Prakash Krishnan, Pedro Moreno, George Dangas, Roxana Mehran
Journal: Journal of the American College of Cardiology (2016)
TCT-78 Incidence and Outcomes of Vascular Complications and Bleeding Events in Patients undergoing TAVR in contemporary U.S. practice: Insights from the STS/ACC TVT Registry®
Authors: Matthew Sherwood, Qun Xiang, Roland Matsouaka, G. Chad Hughes, Sreekanth Vemulapalli, Amit Vora, Eric Peterson, Sunil Rao
Journal: Journal of the American College of Cardiology (2016)
Management of anemia in patients with congestive heart failure
Authors: Lawrence Tim Goodnough, Josep Comin‐Colet, Santiago Leal‐Noval, Sherri Ozawa, Jacqueline Takere, David Henry, Mazyar Javidroozi, Benjamin Hohmuth, Elvira Bisbe, Irwin Gross, Aryeh Shander
Journal: American Journal of Hematology (2016)

Anemia is an independent risk factor for adverse patient outcomes. There are no guidelines for management of anemia in patients with congestive heart failure (CHF), despite its high incidence. Four objectives were defined by the International Anemia Management and Clinical Outcomes Expert Panel (AMCO), a multinational group of interdisciplinary experts identified by the Society for the Advancement of Blood Management (SABM) to: determine the prevalence of anemia in outpatients; to determine the prevalence of hospital-acquired anemia; to assess the impact of anemia management on clinical outcomes such as quality of life and functional status; and to provide recommendations for primary care physicians and specialists for the diagnosis, evaluation, and management of anemia in patients with CHF. Anemia and iron deficiency were confirmed to be highly prevalent in patients with CHF. Intravenous iron therapy improves anemia, cardiac function and exercise tolerance, leading to improvement in quality of life. Anemia management has been demonstrated to be cost-effective. Clinical care pathways to manage anemia in patients with CHF are recommended as best practices in order to improve patient outcomes. Am. J. Hematol. 92:88-93, 2017. © 2016 Wiley Periodicals, Inc.
Daylight saving is linked to depression, Danish study finds
Authors: Jacqui Wise
Journal: BMJ (2016)

Putting the clocks back in autumn is associated with an increase in the rate of unipolar depressive episodes, research published in Epidemiology has found.1

Daylight saving time, which involves changing clocks to one hour later in spring and one hour earlier in autumn, has been introduced in more than 70 countries. The purpose of these time transitions is …
Aneurysm of the Membranous Ventricular Septum
Authors: Kabi P. Misra, Frank J. Hildner, Lawrence S. Cohen, Onkar S. Narula, Philip Samet
Journal: New England Journal of Medicine (1970)

We have observed three cases of aneurysm of the membranous ventricular septum. All had previously been studied, and no patient was found to have had the aneurysm at the first study. All had small ventricular septal defects, normal intracardiac pressures and small left-to-right shunts. Selective angiography accurately defined the aneurysms. Follow-up periods were three to seven years. These newly appearing aneurysms, associated with small ventricular septal defects, suggest another mechanism for their formation, apart from the congenital origin generally accepted: they may be a prelude to spontaneous closure of ventricular septal defects.
TCT-133 Use of a Micro-axial Percutaneous Left Ventricular Assist Device (pLVAD) for Patients with Cardiogenic Shock
Authors: Shayan Nabavi Nouri, Koji Takeda, Veli Topkara, Sanjog Kalra, Leonid Garber, Darshan Doshi, Dimitri Karmpaliotis, Melana Yuzefpolskaya, Hiroo Takayama, Yoshifumi Naka, Paolo Colombo, Ajay Kirtane, Arthur Reshad Garan
Journal: Journal of the American College of Cardiology (2016)
Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression
Authors: Charles R. Conway, Mark S. George, Harold A. Sackeim
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
CD58-Negtive Leukemia Initiating Cells Are Independently Associated with High Risk of Relapse in B-Precursor Acute Lymphoblastic Leukemia: A Comprehensive Clinical and Biological Profiling Study
Authors: Yuan Kong, Yanrong Liu, Honghu Zhu, Qian Jiang, Hao Jiang, Lan-Ping Xu, Dai-Hong Liu, Guo-Rui Ruan, Bin Jiang, Kaiyan Liu, Xiao-jun Huang
Journal: Blood (2012)
TCT-516 Instantaneous-wave Free Ratio and Fractional Flow Reserve Comparison in Patients with and Without Severe Aortic Valve Stenosis.
Authors: Roberto Scarsini, Gabriele Pesarini, Carlo Zivelonghi, Anna Piccoli, Alessia Gambaro, Corrado Vassanelli, Flavio Ribichini
Journal: Journal of the American College of Cardiology (2016)
TCT-195 Predictors of Recurrent Acute Coronary Syndrome Hospitalisations Following Acute Myocardial Infarction
Authors: Matias Yudi, Nick Andrianopoulos, Jessica O'Brien, Laura Selkrig, David Clark, Andrew Ajani, Chin Hiew, William Chan, Chris Reid, Omar Farouque, Anthony Dart, Stephen Duffy
Journal: Journal of the American College of Cardiology (2016)
PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Non–Small Cell Lung Cancer
Authors: Wade T. Iams, Hui Yu, Yu Shyr, Tejas Patil, Leora Horn, Caroline McCoach, Karen Kelly, Robert Doebele, David R. Camidge
Journal: Journal of Thoracic Oncology (2016)
TCT-539 Comparison between Instantaneous Wave-Free Ratio and Fractional Flow Reserve versus Morphometric Assessments by Intracoronary Imaging Devices
Authors: Kensuke Matsushita, Kiyoshi Hibi, Kozo Okada, Yasushi Matsuzawa, Yuichiro Kimura, Nobuhiko Maejima, Noriaki Iwahashi, Anton Moritz, Toshiaki Ebina, Peter J. Fitzgerald, Yasuhiro Honda, Kazuo Kimura
Journal: Journal of the American College of Cardiology (2016)
Risk Factors for BK Viruria and Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplant (HSCT) Recipients.
Authors: Wassim McHayleh, Rajesh Sehgal, Walid El-Ayass, Shahid Husain, Parmjeet Randhawa, Michael Boyiadzis, Anastasios Raptis, Mounzer Agha, Markus Mapara
Journal: Blood (2007)
P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program
Authors: Frederico Cappuzzo, Martin Reck, Vassiliki Papadimitrakopoulou, Robert Jotte, Howard West, Tony Mok, Alan Sandler, Simonetta Mocci, Shelley Coleman, Takashi Asakawa, Mark Socinski
Journal: Journal of Thoracic Oncology (2017)
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study
Authors: L. Elit, A. Lee, J. Julian, P. Hoskins, D. Julian, S. Parpia, M. Levine
Journal: Journal of Clinical Oncology (2009)

e16529 Background: Up to 17% of women with ovarian cancer (OC) develop venous thromboembolism (VTE). LMWH reduces the risk of VTE and may have antineoplastic effects because tissue factor on OC cells stimulates tumor growth. A multicentre, open-label phase II randomized trial was undertaken to identify a potentially efficacious and safe dose of dalteparin to investigate its antineoplastic potential in OC. Methods: Women with newly diagnosed epithelial OC were randomized to receive taxane and platinum chemotherapy (CT) and one of 3 doses of dalteparin (50 IU/kg, 100 IU/kg, or 150 IU/kg) subcu daily during the first 3 cycles of CT. With each cycle of CT, patients had a CA125 and were assessed for bleeding or VTE. A response was defined as a ≥50% reduction in CA125 from baseline sustained for at least 28 days (according to GCIG criteria). To select the best LMWH group with a ≥ 80% response rate (RR) {vs. 60% with CT alone} with 90% probability, 39 patients per group were needed. Patients were followed until the end of CT. Results: 77 women were randomized and 72 of them completed follow-up. Compliance with injections was &gt; 80%. There were no major bleeding events and 3 patients in the highest dose group had minor bleeding. There were no VTEs while on or within 7 days of finishing LMWH. There were 2 deaths attributed to the underlying OC. A 50% drop in CA125 by the start of cycle 4 was seen in 87% of the 50 IU/kg group, 92% of the100 IU/kg group, and 84% of the 150 IU/kg group, respectively. The corresponding RRs by the end of cycle 6 were 91%, 92% and 92%. Conclusions: Use of dalteparin is safe and well tolerated in women who are receiving CT for newly diagnosed OC. This therapy was effective in preventing VTE. A dose response effect on CA125 levels was not identified. [Table: see text]
TCT-322 The Smoker’s Paradox Revisited: A 5-Year Patient-Level Pooled Analysis of 17 Randomized Controlled Trials
Authors: None mayank yadav, Philippe Généreux, Bjorn Redfors, Mahesh Madhavan, Ajay Kirtane, Rupa Parvataneni, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
Allogeneic Hematopoietic Cell Transplantation (HCT) for Neuroblastoma (NB): The CIBMTR Experience
Authors: Gregory A. Hale, Stephan A Grupp, Kimberly A. Kasow, Michael R. Bishop, Menachem Bitan, Richard Childs, Edward A. Copelan, Mitchell S. Cairo, Bruce Camitta, Ka Wah Chan, Stella M. Davies, Miguel A. Diaz, John J Doyle, Robert Peter Gale, Vicent M. Gonzalez, Biljana N. Horn, Sonata Jodele, Naynesh R. Kamani, Hillard M. Lazarus, Victor A. Lewis, Kasiani C. Myers, Michael A. Pulsipher, Muna Qayed, Jean Sanders, Peter J. Shaw, Sandeep Soni, Edward A. Stadtmauer, Patrick Stiff, Donna A. Wall, Mukta Arora
Journal: Blood (2011)
TCT-589 Effectiveness of Excimer Laser Coronary Angioplasty with Optical Coherence Tomography Guidance for In-stent Restenosis after Drug Eluting Stent Implantation
Authors: Sho Hashimoto, Akihiko Takahashi, Takeshi Yamada, Yukio Mizuguchi, Norimasa Taniguchi, Shunsuke Nakajima, Tetsuya Hata
Journal: Journal of the American College of Cardiology (2016)